| Date | Title | | | 09/08/10 | Inspire Announces Webcast of Presentation at Stifel Nicolaus Healthcare Conference| DURHAM, N.C.--(BUSINESS WIRE)--Inspire Pharmaceuticals, Inc. (NASDAQ: ISPH - News) announced today that Adrian Adams, President and CEO, will present at the Stifel Nicolaus 2010 Healthcare Conference on Wednesday, September 15, 2010 at 2:40 pm ET in Boston, MA.
The webcast of the presentation will be available on Inspire’s web site at www.inspirepharm.com. An archived version of the webcast presentation will also be available through this link for a limited time following the conference.
Abo... |
|  | | 09/01/10 | Inspire Names Robert Savel as Senior Vice President and Chief Technical Officer| DURHAM, N.C., Sep 01, 2010 (BUSINESS WIRE) -- Inspire Pharmaceuticals, Inc. (NASDAQ: ISPH) announced today the appointment of Robert M. Savel, II, to the position of Senior Vice President and Chief Technical Officer, effective September 20, 2010. In this role, Mr. Savel will be responsible for all manufacturing and technical operations and will report directly to Adrian Adams, President and CEO.
"We are pleased to add Bob to the Inspire leadership team in the important role of Chief Technica... |
| | | 08/25/10 | Inspire Announces Amendment to Ophthalmic Collaboration| DURHAM, N.C., Aug 25, 2010 (BUSINESS WIRE) -- Inspire Pharmaceuticals, Inc. (NASDAQ: ISPH) announced today it has entered into an Amended and Restated License, Development and Marketing Agreement with Allergan, Inc., which revises terms related to the PROLACRIA(TM) (diquafosol tetrasodium ophthalmic solution) 2% development program and Inspire's right to receive revenues from Allergan based on net sales of RESTASIS(R) (cyclosporine ophthalmic emulsion) 0.05% and any other human ophthalmic formul... |
| | | 08/13/10 | Inspire Names Dr. Charles Johnson as Executive Vice President of Research and Development and Chief Medical Officer| - Experienced Pulmonologist and Cystic Fibrosis Drug Development Expert Joins Inspire -
DURHAM, N.C., Aug 13, 2010 (BUSINESS WIRE) -- Inspire Pharmaceuticals, Inc. (NASDAQ: ISPH) announced today it has entered into an Executive Employment Agreement with Charles A. Johnson, M.D., who will become Executive Vice President of Research and Development and Chief Medical Officer, effective September 15, 2010.
Dr. Johnson, age 60, is an accomplished pulmonologist and pharmaceutical executive with... |
| | | 08/05/10 | Inspire Announces Webcast of Presentation at Bank of America Merrill Lynch Specialty Pharmaceuticals Conference| DURHAM, N.C., Aug 05, 2010 (BUSINESS WIRE) -- Inspire Pharmaceuticals, Inc. (NASDAQ: ISPH) announced today that Adrian Adams, President and CEO, will present at the Bank of America Merrill Lynch 2010 Specialty Pharmaceuticals Conference Thursday, August 12, 2010 at 3:40 pm ET in Southampton, NY.
The webcast of the presentation will be available on Inspire's web site at www.inspirepharm.com. An archived version of the webcast presentation will also be available through this link for a limited... |
| | | 08/05/10 | Inspire Reports Second Quarter 2010 Financial Results| Second Quarter 2010 AZASITE(R) Revenue Increased 27% from Second Quarter 2009
DURHAM, N.C., Aug 05, 2010 (BUSINESS WIRE) -- Inspire Pharmaceuticals, Inc. (NASDAQ: ISPH) announced today financial results for the second quarter ended June 30, 2010, reporting a net loss of $8.8 million or ($0.11) per share, an improvement from the second quarter of 2009 during which the Company incurred a net loss of $9.5 million or ($0.17) per share.
Total revenue for the second quarter of 2010 was $27.3 mi... |
| | | 07/22/10 | Inspire Announces Date for Conference Call and Webcast to Discuss Second Quarter 2010 Financial Results| DURHAM, N.C., Jul 22, 2010 (BUSINESS WIRE) -- Inspire Pharmaceuticals, Inc. (NASDAQ:ISPH) announced today that it plans to report second quarter 2010 financial results on Thursday, August 5, 2010 before the market opens. Inspire's President and CEO, Adrian Adams, and Executive Vice President and CFO, Thomas R. Staab, II, will host a conference call and live webcast with an accompanying slide presentation on Thursday, August 5, 2010 at 8:00 a.m. ET.
The live webcast and replay will be availab... |
| | | 07/01/10 | Inspire Announces Management Structure Changes| DURHAM, N.C., Jul 01, 2010 (BUSINESS WIRE) --Inspire Pharmaceuticals, Inc. (NASDAQ: ISPH) announced today a series of management changes, including revised job responsibilities, designed to position the organization for long-term success.
"The actions we are taking provide the organizational structure and additional leadership needed to achieve our strategic objectives and drive shareholder value," said Adrian Adams, President and CEO of Inspire. "During my first four months as CEO at Inspir... |
| | | 06/17/10 | New Data Presented At ECFS Conference Highlight Potential for
Denufosol to Provide Benefit to Adolescent Cystic Fibrosis Patients and
Patients on Minimal Pharmacotherapies| DURHAM, N.C., Jun 17, 2010 (BUSINESS WIRE) --Inspire Pharmaceuticals, Inc. (NASDAQ: ISPH) announced today that data
is being presented on denufosol tetrasodium, an investigational therapy
for cystic fibrosis (CF), during an oral presentation and poster
presentations at the 33rd Annual European Cystic Fibrosis
Society (ECFS) Conference June 16 - 19, 2010 in Valencia, Spain. The
data from Inspire's first Phase 3 clinical trial with denufosol,
TIGER-1... |
| | | 06/03/10 | Inspire Announces Webcasts of Presentations at Needham Healthcare
Conference and Jefferies Life Sciences Conference| DURHAM, N.C., Jun 03, 2010 (BUSINESS WIRE) --Inspire Pharmaceuticals, Inc. (NASDAQ:ISPH) announced today that Adrian
Adams, President and CEO, and Thomas R. Staab, II, Executive Vice
President and CFO, will present at the Needham & Company 9th Annual
Healthcare Conference Thursday, June 10 at 2:40 pm ET and the Jefferies
2010 Global Life Sciences Conference Friday, June 11 at 9:00 am ET in
New York City.
The webcasts of the presentations will be ava... |
| | | 05/19/10 | Data Suggest Denufosol May Hold Promise as an Early Intervention
Treatment for Cystic Fibrosis| ATS Oral Presentation Highlights Denufosol's Potential to Reach the
Small Airways, Where CF Lung Disease Begins
DURHAM, N.C., May 19, 2010 (BUSINESS WIRE) --Inspire Pharmaceuticals, Inc. (NASDAQ: ISPH) announced today that
Inspire scientists and collaborators will present data on denufosol
tetrasodium, an investigational therapy for cystic fibrosis (CF), during
an oral presentation at the American Thoracic Society (ATS) 2010
International Conference May... |
| | | 05/11/10 | Inspire Announces Grants under NASDAQ Marketplace Rule 5635| DURHAM, N.C., May 11, 2010 (BUSINESS WIRE) --Inspire Pharmaceuticals, Inc. (NASDAQ:ISPH) announced today the approval
of non-qualified stock option ("Options") and restricted stock unit
("RSUs") grants to Inspire's Executive Vice President and Chief
Administrative and Legal Officer, Andrew I. Koven, pursuant to NASDAQ
Marketplace Rule 5635(c)(4).
On May 10, 2010, Inspire granted Mr. Koven the Options to purchase
200,000 shares of Inspire's common stock.... |
| | | 05/03/10 | Inspire Reports First Quarter 2010 Financial Results| - First Quarter 2010 Revenue Increased 54% from First Quarter 2009 -
DURHAM, N.C., May 03, 2010 (BUSINESS WIRE) --Inspire Pharmaceuticals, Inc. (NASDAQ: ISPH) announced today financial
results for the first quarter ended March 31, 2010, reporting a net loss
of $14.8 million or ($0.18) per share.
Total revenue for the first quarter of 2010 was $22.1 million, as
compared to $14.3 million for the first quarter of 2009, reflecting an
increase of 54%. Revenue fro... |
| | | 04/27/10 | Inspire Announces Webcast of Presentation at Deutsche Bank Health
Care Conference| DURHAM, N.C., Apr 27, 2010 (BUSINESS WIRE) --Inspire Pharmaceuticals, Inc. (NASDAQ: ISPH) announced today that Adrian
Adams, President and CEO, will present at the Deutsche Bank 35th Annual
Health Care Conference on Tuesday May 4, 2010 at 9:20 am ET in Boston,
MA.
The webcast of the presentation will be available on Inspire's web site
at www.inspirepharm.com.
An archived version of the webcast presentation will also be available
through this lin... |
| | | 04/19/10 | Inspire Announces Date for Conference Call and Webcast to Discuss
First Quarter 2010 Financial Results| DURHAM, N.C., Apr 19, 2010 (BUSINESS WIRE) --Inspire Pharmaceuticals, Inc. (NASDAQ:ISPH) announced today that it
plans to report first quarter 2010 financial results on Monday, May 3,
2010. Inspire's President and CEO, Adrian Adams, and Executive Vice
President and CFO, Thomas R. Staab, II, will host a conference call and
live webcast on Monday, May 3, 2010 at 10:00 a.m. ET.
To access the conference call, U.S. participants may call (877) 648-7970
and in... |
| | | 04/16/10 | Santen and Inspire Announce Approval of DIQUAS™ for Dry Eye Treatment in Japan | April 16, 2010 --- Osaka, Japan and Durham, NC --- Santen Pharmaceutical Co., Ltd. (Listed in TSE : 4536) and Inspire Pharmaceuticals, Inc. (NASDAQ: ISPH) announced today that the Japanese Ministry of Health, Labour and Welfare granted approval for the new dry eye treatment drug, DIQUAS Ophthalmic Solution 3% (generic name: diquafosol tetrasodium), on April 16, 2010.
Diquafosol was licensed for certain ophthalmic uses from Inspire and DIQUAS Ophthalmic Solution 3% was developed by Santen as a ... |
| | | 04/13/10 | Inspire Appoints Andrew Koven as Executive Vice President and Chief
Administrative and Legal Officer| DURHAM, N.C., Apr 13, 2010 (BUSINESS WIRE) --Inspire Pharmaceuticals, Inc. (NASDAQ: ISPH) announced today it will
name Andrew I. Koven to the newly created position of Executive Vice
President and Chief Administrative and Legal Officer, effective May 10,
2010.
"I am pleased to announce the addition of Andrew to our experienced
senior management team," stated Adrian Adams, President and CEO of
Inspire. "Andrew is an accomplished business and legal profes... |
| | | 03/15/10 | Inspire Announces Results From AZASITE(R) Phase 2 Blepharitis Trials and Plans to Continue Clinical Development in Anterior and Posterior Blepharitis| DURHAM, N.C., Mar 15, 2010 (BUSINESS WIRE) -- Inspire Pharmaceuticals, Inc. (NASDAQ: ISPH) announced today the results from two Phase 2 clinical trials with AZASITE (azithromycin ophthalmic solution) 1% for the treatment of blepharitis. Inspire will conduct additional clinical work to continue pursuing a potential indication for treatment of anterior and posterior forms of blepharitis.
The initial Phase 2 work consisted of two clinical trials in patients with anterior blepharitis, one with a t... |
| | | 03/04/10 | Inspire Reports Fourth Quarter and Full Year 2009 Financial Results| - Fourth Quarter Revenue Increased 57% and Net Loss Decreased 74%
-- Full Year Revenue Increased 31% and Net Loss Decreased 23% -
DURHAM, N.C., Mar 04, 2010 (BUSINESS WIRE) -- Inspire Pharmaceuticals, Inc. (NASDAQ: ISPH) announced today financial results for the fourth quarter and year ended December 31, 2009, reporting a net loss of $2.6 million or ($0.03) per share for the fourth quarter and a net loss of $40.0 million or ($0.60) per share for the full year.
Total revenue for the fourth qu... |
| | | 03/02/10 | Inspire Announces Webcast of Presentation at Cowen Health Care Conference| DURHAM, N.C., Mar 02, 2010 (BUSINESS WIRE) -- Inspire Pharmaceuticals, Inc. (NASDAQ: ISPH) announced today that Adrian Adams, President and CEO, and Thomas R. Staab, II, Executive Vice President and CFO, will present at the Cowen and Company 30th Annual Health Care Conference Monday, March 8, 2010 at 4:00 pm ET in Boston, MA.
The webcast of the presentation will be available on Inspire's web site at www.inspirepharm.com. An archived version of the webcast presentation will also be available th... |
| | | 03/01/10 | Inspire Elects George Abercrombie to Board of Directors| DURHAM, N.C., Mar 01, 2010 (BUSINESS WIRE) -- Inspire Pharmaceuticals, Inc. (NASDAQ: ISPH) announced today the
election of George B. Abercrombie to its Board of Directors, effective
March 1, 2010. Mr. Abercrombie will also serve as a member of the Audit
Committee of the Board.
Mr. Abercrombie, age 55, most recently served as the President and CEO
of Hoffmann-La Roche Inc. ("Roche") and Head of North American
Pharmaceutical Operations from 2001 through Dec... |
| | | 02/26/10 | Inspire Announces Date for Conference Call and Webcast to Discuss
Fourth Quarter and Full Year 2009 Financial Results| DURHAM, N.C., Feb 26, 2010 (BUSINESS WIRE) -- Inspire Pharmaceuticals, Inc. (NASDAQ: ISPH) announced today that it
plans to report fourth quarter and full year 2009 financial results on
Thursday, March 4, 2010 before the market opens. Inspire's President and
CEO, Adrian Adams, and Executive Vice President and CFO, Thomas R.
Staab, II, will host a conference call and live webcast on Thursday,
March 4, 2010 at 10:00 a.m. ET.
To access the conference call, U... |
| | | 02/23/10 | Inspire Announces Grants Under NASDAQ Marketplace Rule 5635| DURHAM, N.C., Feb 23, 2010 (BUSINESS WIRE) -- Inspire Pharmaceuticals, Inc. (NASDAQ: ISPH) announced today the
approval of non-qualified stock option ("Options") and restricted stock
unit ("RSUs") grants to Inspire's President and CEO, Adrian Adams,
pursuant to NASDAQ Marketplace Rule 5635(c)(4).
On February 22, 2010, Inspire granted Mr. Adams the Options to purchase
350,000 shares of Inspire's common stock. The Options have an exercise
price of $6.35, wh... |
| | | 02/19/10 | Inspire Names Adrian Adams as President and Chief Executive Officer| Former President and CEO of Kos Pharmaceuticals, Inc. and Sepracor Inc. Joins InspireDURHAM, N.C., Feb 19, 2010 (BUSINESS WIRE) -- Inspire Pharmaceuticals, Inc. (NASDAQ: ISPH) announced today it has
named Adrian Adams as President and Chief Executive Officer (CEO) of
Inspire, and elected Mr. Adams to its Board of Directors, both effective
February 22, 2010.
Mr. Adams, age 59, is a highly qualified pharmaceutical executive who
most recently successfully led the gr... |
| | | 02/04/10 | Inspire Announces Webcast of Presentation at BIO CEO Conference| DURHAM, N.C., Feb 04, 2010 (BUSINESS WIRE) -- Inspire Pharmaceuticals, Inc. (NASDAQ: ISPH) announced today that
Inspire senior management will present at the BIO CEO & Investor
Conference Tuesday, February 9, 2010 at 11:00 am ET in New York City.
The webcast of the presentation will be available on Inspire's web site
at www.inspirepharm.com.
An archived version of the webcast presentation will also be available
through this link for a limited time fol... |
| | | 01/21/10 | Inspire Announces Results of Phase 3 PROLACRIA(TM) Trial for Dry Eye| - Primary and Secondary Endpoints Not Met -DURHAM, N.C., Jan 21, 2010 (BUSINESS WIRE) -- Inspire Pharmaceuticals, Inc. (NASDAQ: ISPH) announced today that its Phase 3 clinical trial (Trial 03-113) of PROLACRIA(TM) (diquafosol tetrasodium ophthalmic solution) 2% for the treatment of dry eye disease did not meet its primary endpoint (p = 0.526) or its secondary endpoint (p = 0.368).
"We have provided the top-line results from this trial to our partner Allergan and we will be conducting a thoroug... |
| | | 01/07/10 | Inspire Announces Webcast of Presentation at J.P. Morgan Healthcare
Conference| DURHAM, N.C., Jan 07, 2010 (BUSINESS WIRE) -- Inspire Pharmaceuticals, Inc. (NASDAQ:ISPH) announced today that Inspire
senior management will present at the 28th Annual J.P. Morgan
Healthcare Conference on Thursday, January 14, 2010 at 12:00 pm local
time in San Francisco, CA.
The webcast of the presentation will be available on Inspire's web site
at www.inspirepharm.com.
An archived version of the webcast presentation will also be available
throu... |
| |
|
